TIDMETX

RNS Number : 3245U

e-Therapeutics plc

01 August 2022

e-therapeutics plc

("e-therapeutics" or the "Company")

Filing of eight patent applications on

proprietary GalNAc-siRNA technology and target related innovation

London, UK, 1 August 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, today announced the filing of eight further patent applications in the United States ("US") to protect innovation arising from e-therapeutics' proprietary GalNAc-siRNA technology.

The Company uses its proprietary GalNAc-siRNA technology to silence any gene in liver hepatocytes. As announced on 26 October 2021, e-therapeutics' GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

The eight patent applications relate to innovation arising from the Company's work on its pipeline of pre-clinical siRNA candidates in several therapeutic areas and include innovation around novel target ideas and associated disease-relevant biology identified using the Company's computational platform, novel siRNA therapeutics and novel siRNA chemistries associated with such siRNA therapeutics.

This news follows e-therapeutics' announcement on 4 May 2022, as part of its year-end results statement, that eleven patent applications had been filed to protect proprietary and novel GalNAc-siRNA silencing construct designs.

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

"This second announcement of significant patent filings within three months demonstrates fast and meaningful scientific and technological progress. It also reflects our commitment to protecting the Company's proprietary innovation, which forms a critical part of our strategy as we continue to make material steps in developing a computationally driven in-house pipeline of highly differentiated RNAi medicines at speed. Our computational platform not only affords us an important advantage in drug discovery, but also in IP strategy, and we are leveraging this position in our patent applications."

Enquiries:

 
    e-therapeutics plc 
    Ali Mortazavi, CEO                                   Tel: +44 (0)20 4551 
     James Chandler, VP IR & Communications                             8888 
                                                     www.etherapeutics.co.uk 
                                                  -------------------------- 
 
 
     SP Angel Corporate Finance LLP 
                                                     Tel: +44(0)20 3470 0470 
                                                  -------------------------- 
    Nominated Adviser and Broker 
                                                  -------------------------- 
    Matthew Johnson/Caroline Rowe (Corporate 
     Finance) 
                                                  -------------------------- 
    Vadim Alexandre/Rob Rees (Corporate Broking) 
                                                  --------------------------

About e-therapeutics plc

e-therapeutics plc is a UK-based company integrating computational power and biological insight to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease- and modality-agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to capture and interrogate human disease complexity more fully.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and screening. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFVEDIIAFIF

(END) Dow Jones Newswires

August 01, 2022 02:00 ET (06:00 GMT)

E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas E-therapeutics.
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas E-therapeutics.